Metoclopramide Noridem (Metoclopramide Hydrochloride Monohydrate)

Metoclopramide antagonizes dopamine D2 receptors in the chemoreceptor trigger zone, reducing the central stimulus for vomiting. At the same time, it enhances acetylcholine release in the gut, which increases smooth‑muscle contractions and promotes faster gastric emptying.

The appropriate dose of Metoclopramide Noridem is determined by the prescribing clinician based on the patient’s condition, age, renal function and response to therapy. Dosage regimens are individualized and should follow local prescribing guidelines.

Safety data for Metoclopramide in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoclopramide differs from many antiemetics by also having pro‑kinetic activity, which can be advantageous in gastroparesis. Compared with pure dopamine antagonists or serotonin antagonists, it offers both anti‑nausea and gastric motility benefits, though it may carry a higher risk of extrapyramidal side effects.

Metoclopramide Noridem should be stored at ambient temperature, below 25 °C, in its original container. Protect the product from moisture, direct sunlight and extreme temperature fluctuations to maintain its stability.

The medication is supplied as an injectable solution and can be given either intramuscularly or intravenously by a qualified healthcare professional. The route, rate and volume of administration are determined by the prescriber according to the clinical situation.

Serious risks include extrapyramidal reactions such as acute dystonia, tardive dyskinesia with long‑term use, neuroleptic malignant syndrome, severe depression or suicidal thoughts, seizures, and rare anaphylactic reactions. Patients should be monitored closely for these events.

Metoclopramide is contraindicated in individuals with known hypersensitivity to the drug, those with a history of tardive dyskinesia, and patients taking certain MAO inhibitors. Caution is also advised for patients with seizure disorders, severe depression, or significant renal impairment.